<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3439">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839965</url>
  </required_header>
  <id_info>
    <org_study_id>AP-017</org_study_id>
    <nct_id>NCT04839965</nct_id>
  </id_info>
  <brief_title>Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of IV Ampion in Adult COVID-19 Patients Requiring Oxygen Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ampio Pharmaceuticals. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ampio Pharmaceuticals. Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 randomized study to evaluate the safety and efficacy of IV Ampion in&#xD;
      improving the clinical course and outcomes of adult COVID-19 patients requiring supplemental&#xD;
      oxygen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ampion is the low molecular weight filtrate of human serum albumin with the in vitro ability&#xD;
      to modulate inflammatory cytokine levels. Ampion has the potential to improve clinical&#xD;
      outcomes for COVID-19 patients by reducing inflammatory cytokines correlated with the&#xD;
      disease.&#xD;
&#xD;
      This study aims to evaluate Ampion and clinical outcomes in patients with COVID-19 requiring&#xD;
      supplemental oxygen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of Ampion compared to placebo on mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>Mortality measured as the percentage of participants with a successful outcome (life) or unsuccessful outcome (death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerability of Ampion compared to placebo on incidence and severity of adverse events</measure>
    <time_frame>Baseline to Day 60</time_frame>
    <description>Incidence of adverse events (AEs) and serious adverse events (SAEs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>IV Ampion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ampion administered via intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered via intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ampion</intervention_name>
    <description>Ampion administered via intravenous infusion</description>
    <arm_group_label>IV Ampion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo administered via intravenous infusion</description>
    <arm_group_label>IV placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, ≥ 18 years old&#xD;
&#xD;
          2. Diagnosed with COVID-19, as evaluated by laboratory diagnostic test or diagnosis based&#xD;
             on radiological clinical findings&#xD;
&#xD;
          3. Baseline severity categorization of severe or critical COVID-19 infection per FDA&#xD;
             Guidance for developing drugs and biological products for COVID-19 (February 2021)&#xD;
&#xD;
               1. Severe COVID-19&#xD;
&#xD;
                    -  Symptoms suggestive of severe systemic illness with COVID-19, which include&#xD;
                       shortness of breath or respiratory distress&#xD;
&#xD;
                    -  Clinical signs indicative of severe systemic illness with COVID-19, such as&#xD;
                       respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, SpO2 ≤ 93% on&#xD;
                       room air at sea level (SpO2 ≤ 90% at altitude) or PaO2/FiO2 &lt; 300&#xD;
&#xD;
               2. Critical COVID-19&#xD;
&#xD;
                    -  Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen&#xD;
                       delivered via reinforced cannula at flow rates &gt;20 l/min with fraction&#xD;
                       oxygen ≥ 0.5) or&#xD;
&#xD;
                    -  Non-invasive mechanical or endotracheal mechanical ventilation&#xD;
&#xD;
          4. Informed consent obtained from the patient or the patient's legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. As a result of the medical review and screening investigation, the Principal&#xD;
             Investigator considers the patient unfit for the study and/or progression to death is&#xD;
             imminent and inevitable irrespective of the provision of treatments.&#xD;
&#xD;
          2. Clinical diagnosis of respiratory failure (therapy not able to be administered in&#xD;
             setting of resource limitation)&#xD;
&#xD;
          3. Shock defined by systolic blood pressure &lt;90 mm Hg, or diastolic blood pressure &lt;60 mm&#xD;
             Hg or requiring vasopressors.&#xD;
&#xD;
          4. Multi-organ dysfunction/failure&#xD;
&#xD;
          5. Patient has severe chronic obstructive or restrictive pulmonary disease (COPD) (as&#xD;
             defined by prior pulmonary function tests), chronic renal failure, or significant&#xD;
             liver abnormality (e.g., cirrhosis, transplant, etc.).&#xD;
&#xD;
          6. Patient has chronic conditions requiring chemotherapy or immunosuppressive medication.&#xD;
&#xD;
          7. A history of allergic reactions to human albumin (reaction to non-human albumin such&#xD;
             as egg albumin is not an exclusion criterion) or ingredients in 5% human albumin&#xD;
             (N-acetyltryptophan, sodium caprylate).&#xD;
&#xD;
          8. Prolonged QT interval.&#xD;
&#xD;
          9. Patient has known pregnancy or is currently breastfeeding.&#xD;
&#xD;
         10. Patient planning to become pregnant, or father a child, during the treatment and&#xD;
             follow-up period and/or is not willing to remain abstinent or use contraception.&#xD;
&#xD;
         11. Participation in another clinical trial (not including treatments for COVID-19 as&#xD;
             approved by the FDA through expanded access, emergency, or compassionate use), or&#xD;
             participation in a trial such that enrollment in this study would fall within the time&#xD;
             frame of the half-life of the other investigational product(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ampio Pharmaceuticals</last_name>
    <phone>720-437-6500</phone>
    <email>ClinicalTrials@ampiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ampio Pharmaceuticals</last_name>
      <phone>720-437-6500</phone>
      <email>ClinicalTrials@ampiopharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

